Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Top Cited Papers
- 20 April 2008
- journal article
- review article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 333 (1-2) , 1-9
- https://doi.org/10.1016/j.jim.2008.01.001
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeuticsJournal of Immunological Methods, 2007
- Immunogenicity, efficacy and adverse events of adalimumab in RA patientsRheumatology International, 2006
- Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.Blood, 2005
- Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodiesJournal of Pharmaceutical and Biomedical Analysis, 2005
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Thrombocytopenia caused by the development of antibodies to thrombopoietinBlood, 2001
- Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic SubjectsAmerican Journal of Respiratory and Critical Care Medicine, 1999
- EXPRESSION OF ACTIVE THROMBOPOIETIN AND IDENTIFICATION OF ITS KEY RESIDUES RESPONSIBLE FOR RECEPTOR BINDINGCytokine, 1998
- Increased IgA antibodies to cytokeratins in the spondyloarthropathies.Annals of the Rheumatic Diseases, 1994